Khaity Abdulrhman, Albakri Khaled, Al-Dardery Nada Mostafa, Yousef Yaman A S, Foppiani Jose A, Lin Samuel J
Faculty of Medicine, Elrazi University, Khartoum, Sudan.
Faculty of Medicine, The Hashemite University, Zarqa, Jordan.
Plast Surg (Oakv). 2025 May;33(2):318-328. doi: 10.1177/22925503231195017. Epub 2023 Aug 21.
Hypertrophic and keloid scars are abnormal tissue growth that can be disfiguring, for which the available treatment has not yielded consistent results. Therefore, this study aimed to evaluate the capability of Adipose tissue-derived stem cell (ADSC) therapy in treating these scars. A literature search was conducted on PubMed, Scopus, Cochrane Library, and Web of Science from inception until July 2022. We included experimental studies that evaluated ADSCs as a therapy for hypertrophic and keloid scars in both in-vivo and in-vitro models. Our findings extracted from 12 included studies demonstrated that ADSCs have a promising potential in reducing collagen deposition, proliferation, and migration rates of fibroblast, decreasing gene/protein expression of scar-related molecules including levels of TGF-β1 and lowering intracellular signal pathway-related molecules of hypertrophic and keloid scars in both models. However, no significant difference ( > .05) was found in the hypertrophic scar in-vitro models in terms of DCN gene expression. Ultimately, the current studies included in this systematic review support the use of ADSCs to alleviate hypertrophic and keloid scars.
增生性瘢痕和瘢痕疙瘩是会导致毁容的异常组织生长,现有的治疗方法并未产生一致的效果。因此,本研究旨在评估脂肪组织来源干细胞(ADSC)疗法治疗这些瘢痕的能力。从创刊至2022年7月,我们在PubMed、Scopus、Cochrane图书馆和科学网进行了文献检索。我们纳入了在体内和体外模型中评估ADSCs作为增生性瘢痕和瘢痕疙瘩治疗方法的实验研究。我们从12项纳入研究中提取的结果表明,在两种模型中,ADSCs在减少胶原蛋白沉积、成纤维细胞的增殖和迁移率、降低包括TGF-β1水平在内的瘢痕相关分子的基因/蛋白表达以及降低增生性瘢痕和瘢痕疙瘩的细胞内信号通路相关分子方面具有广阔的潜力。然而,在增生性瘢痕体外模型中,在DCN基因表达方面未发现显著差异(>0.05)。最终,本系统评价纳入的当前研究支持使用ADSCs来减轻增生性瘢痕和瘢痕疙瘩。